Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc. is actively advancing its diverse pipeline of vaccines and immunotherapies, including a next-generation COVID-19 vaccine (GEO-CM04S1) and a gene-directed therapy targeting head and neck cancers, which demonstrates significant potential for future revenue generation. The company has garnered regulatory support for its Mpox vaccine, facilitating accelerated development and fostering partnerships for innovative delivery methods, thus enhancing investor confidence. The establishment of a scalable manufacturing platform aligns with public health initiatives, positioning Geovax favorably for sustained growth in an evolving biotech landscape.

Bears say

Geovax Labs Inc. is facing significant execution risk due to low liquidity, a depressed share price, and a challenging financing environment, which raises concerns about the company's near-term outlook. With only $5 million remaining in cash at the end of Q3 and high cash burn from research and development expenses, the likelihood of additional dilution increases as the company struggles to secure necessary funding. The broader biotechnology sector is also experiencing funding pressures, with nearly 40% of public biotechs projected to run out of cash within the next 12 months, further complicating Geovax's financial situation.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.